Table 3.
Adverse Events (AE) Grade ≥3
| AE Grade ≥3 | ||||
|---|---|---|---|---|
| Ruxolitinib (mg, PO, BID) | ||||
| N=27 patients | 50 (n=4) |
100 (n=5) |
200 (n=18) |
Overall (n=27) |
| Thrombocytopenia | 2 | 3 | 6 | 11 |
| Neutropenia | 2 | 2 | 6 | 10 |
| Stroke (ischemic) | 1 | 0 | 2 | 3 |
| Hemorrhage (Pulmonary) | 1 | 1 | 0 | 2 |
| Alkaline phosphatase elevation | 1 | 0 | 0 | 1 |
| Other liver test abrnomality (ALT, AST, Total bilirubin) | 0 | 1 | 0 | 1 |
| Cerebral edema | 1 | 0 | 0 | 1 |
| Fatigue | 0 | 0 | 1 | 1 |
| Mucositis | 0 | 0 | 1 | 1 |
| Headache | 0 | 0 | 1 | 1 |
| INFECTIONS: | ||||
| Pneumonia | 3 | 1 | 11 | 15 |
| Sepsis | 0 | 1 | 4 | 5 |
| Sepsis + other infection | 1 | 0 | 1 | 2 |
| Other (Viral, cellulitis) | 1 | 0 | 3 | 4 |